Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 3
1971 1
1972 2
1975 3
1977 2
1978 1
1979 1
1980 1
1981 2
1982 1
1983 2
1984 7
1985 8
1986 6
1987 9
1988 6
1989 3
1990 2
1991 12
1992 4
1993 6
1994 3
1995 7
1996 2
1997 2
1998 5
1999 1
2000 1
2001 2
2002 2
2003 3
2004 3
2005 2
2006 2
2008 3
2009 4
2010 2
2011 6
2012 5
2013 4
2014 2
2015 3
2016 2
2017 6
2018 5
2019 4
2020 3
2021 2
2022 6
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Results by year

Filters applied: . Clear all
Page 1
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.
Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Park JR, et al. J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. J Clin Oncol. 2017. PMID: 28471719 Free PMC article. Review.
Monthly international conference calls were held from 2011 to 2015, and consensus was reached through review by working group leadership and the National Cancer Institute Clinical Trials Planning Meeting leadership council. Results Overall response in the revised INRC will integr …
Monthly international conference calls were held from 2011 to 2015, and consensus was reached through review by working group leadership and …
Management of Neuroblastoma: ICMR Consensus Document.
Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, Rath GK, Bakhshi S. Bansal D, et al. Indian J Pediatr. 2017 Jun;84(6):446-455. doi: 10.1007/s12098-017-2298-0. Epub 2017 Apr 3. Indian J Pediatr. 2017. PMID: 28367616 Review.
Diagnosis is established by tumor biopsy and elevated urinary catecholamines. Staging is performed using bone marrow and mIBG scan (FDG-PET/bone scan if mIBG unavailable or non-avid). ...High-risk disease includes older children with Stage 4 disease and MYCN …
Diagnosis is established by tumor biopsy and elevated urinary catecholamines. Staging is performed using bone marrow and mIBG …
Advances in the Management of Neuroblastoma.
Qadir MI, Ahmed B, Noreen S. Qadir MI, et al. Crit Rev Eukaryot Gene Expr. 2024;34(2):1-13. doi: 10.1615/CritRevEukaryotGeneExpr.2023049559. Crit Rev Eukaryot Gene Expr. 2024. PMID: 38073438 Review.
There are four main stages of neuroblastoma, and treatment is according to the low and high risk of the disease. Several cytotoxic agents along with other therapies (antibody therapy, gene therapy, and even immunological therapies, antiangiogenic th …
There are four main stages of neuroblastoma, and treatment is according to the low and high risk of the disease. Several cytotoxic agents al …
The new international neuroblastoma response criteria.
Orr KE, McHugh K. Orr KE, et al. Pediatr Radiol. 2019 Oct;49(11):1433-1440. doi: 10.1007/s00247-019-04397-2. Epub 2019 Oct 16. Pediatr Radiol. 2019. PMID: 31620844 Review.
In this review we summarise recent changes to the International Neuroblastoma Response Criteria including the use of RECIST (Response Evaluation Criteria in Solid Tumours) guidance for measurable soft-tissue disease, replacement of technetium-99 m-methylene diphosphonate (MDP) …
In this review we summarise recent changes to the International Neuroblastoma Response Criteria including the use of RECIST (Response Evalua …
Contemporary approach to diagnosis and treatment of neuroblastoma.
Charron M. Charron M. Q J Nucl Med Mol Imaging. 2013 Mar;57(1):40-52. Q J Nucl Med Mol Imaging. 2013. PMID: 23474634 Review.
Other pharmaceuticals such as norcholesterol derivatives, [111In]pentetreotide and [68Ga]somatostatin analogs, [18F]fluorodeoxyglucose, [18F]fluorodopa, [18F]fluorodopamine, [11C]meta hydroxyephedrine, and [11C] /[18F] /[123I]Metomidate (MTO) have been or are being evaluated curr …
Other pharmaceuticals such as norcholesterol derivatives, [111In]pentetreotide and [68Ga]somatostatin analogs, [18F]fluorodeoxyglucose, [18F …
Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
Voeller J, Sondel PM. Voeller J, et al. J Pediatr Hematol Oncol. 2019 Apr;41(3):163-169. doi: 10.1097/MPH.0000000000001369. J Pediatr Hematol Oncol. 2019. PMID: 30897608 Free PMC article. Review.
Neuroblastoma (NBL) is the most common extracranial solid tumor in pediatrics, yet overall survival is poor for high-risk cases. Immunotherapy regimens using a tumor-selective antidisialoganglioside (anti-GD2) monoclonal antibody (mAb) have been studied for several …
Neuroblastoma (NBL) is the most common extracranial solid tumor in pediatrics, yet overall survival is poor for high-risk cases. Immu …
Primary Intracranial pPNET/Ewing Sarcoma: Diagnosis, Management, and Prognostic Factors Dilemma-A Systematic Review of the Literature.
Cherif El Asri A, Benzagmout M, Chakour K, Chaoui MF, Laaguili J, Chahdi H, Gazzaz M, El Mostarchid B. Cherif El Asri A, et al. World Neurosurg. 2018 Jul;115:346-356. doi: 10.1016/j.wneu.2018.04.164. Epub 2018 May 3. World Neurosurg. 2018. PMID: 29729469 Review.
BACKGROUND: Ewing sarcoma (ES) is a malignant bone tumor that is most commonly observed in the long bones, the pelvis, and the chest. ...OBJECTIVE: In the aim of identifying the prognostic factors of this rare localization, we conducted a systematic review of …
BACKGROUND: Ewing sarcoma (ES) is a malignant bone tumor that is most commonly observed in the long bones, the pelvis, …
MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma.
Boubaker A, Bischof Delaloye A. Boubaker A, et al. Q J Nucl Med Mol Imaging. 2008 Dec;52(4):388-402. Q J Nucl Med Mol Imaging. 2008. PMID: 19088693 Free article. Review.
Neuroblastoma (NBL) is the commonest extra-cranial solid tumor in children and the leading cause of cancer related deaths in childhood between the age of 1 to 4 years. ...NBL needs a multimodality approach at diagnosis and during follow-up and MIBG scintigraphy keeps its p …
Neuroblastoma (NBL) is the commonest extra-cranial solid tumor in children and the leading cause of cancer related deaths in childhoo …
Lesions of the skull base: imaging for diagnosis and treatment.
Choudhri AF, Parmar HA, Morales RE, Gandhi D. Choudhri AF, et al. Otolaryngol Clin North Am. 2012 Dec;45(6):1385-404. doi: 10.1016/j.otc.2012.08.008. Otolaryngol Clin North Am. 2012. PMID: 23153754 Review.
This article provides a summary of how to approach the imaging analysis of lesions of the anterior, central, and posterior skull base. The primary focus is tumors and tumor-mimickers, and representative examples are shown to differentiate the features of lesions tha …
This article provides a summary of how to approach the imaging analysis of lesions of the anterior, central, and posterior skull base. The p …
How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Deu in Barcelona, Spain.
Castañeda A, Gorostegui M, Miralles SL, Chamizo A, Patiño SC, Flores MA, Garraus M, Lazaro JJ, Santa-Maria V, Varo A, Muñoz JP, Mora J. Castañeda A, et al. ESMO Open. 2022 Apr;7(2):100462. doi: 10.1016/j.esmoop.2022.100462. Epub 2022 Apr 6. ESMO Open. 2022. PMID: 35397431 Free PMC article. Review.
It was approved in 2020 by the United States Food and Drug Administration (FDA) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for treatment of pediatric and adult patients with relapsed/refractory high-risk neuroblastoma, limited to the bone …
It was approved in 2020 by the United States Food and Drug Administration (FDA) in combination with granulocyte-macrophage colony-stimulatin …
169 results